Small-Cap Q2 Earnings Roundup: Vext Science Margins Expand, EXoZymes Pivots on Biotech Grant, Banzai Acquires ConnectAndSell

The Quick Take

• Vext Science grew adjusted EBITDA 22% sequentially in Q2 as Ohio cannabis operations outpaced losses from the Arizona market wind-down
• EXoZymes secured $20M in non-dilutive grants and achieved 10x enzyme production efficiency gains despite tight cash runway heading into 2027
• Banzai International completed the ConnectAndSell acquisition despite a 27% revenue decline, targeting transformative H2 2026 through new sales automation capabilities

Three small-cap companies across cannabis, biotechnology, and marketing technology reported Q2 2026 earnings sharing a common theme of operational transformation amid financial constraint. Vext Science—an Ohio-focused cannabis multi-state operator—reported 22% sequential adjusted EBITDA growth as its Ohio dispensary network continued to gain market share following the state's 2023 adult-use legalization, while the planned wind-down of underperforming Arizona operations removes a persistent margin drag. The Ohio cannabis market has been one of the strongest adult-use launch markets in US history, with elevated consumer demand and favorable regulatory structure providing durable tailwind for operators with established retail presence and sufficient capital to weather the early license proliferation phase.

EXoZymes achieved a significant operational milestone with a claimed 10x improvement in NCT production efficiency, making a mid-2027 market entry feasible if ongoing clinical development proceeds on schedule. The company's success in securing $20 million in non-dilutive government and institutional grants reduces near-term equity dilution risk—addressing one of the most acute investor concerns for pre-revenue biotech companies with limited cash runway. Banzai International's acquisition of ConnectAndSell—a sales automation and dialing platform—represents a strategic pivot toward technology-enabled revenue generation following a challenging 27% top-line decline, with management projecting that the acquisition will provide accretive contribution through H2 2026 from new customer acquisition capabilities.

These Q2 results illustrate the asymmetric risk-reward profile inherent in small-cap growth investing: significant operational progress can occur simultaneously with financial vulnerability, creating volatile valuation dynamics that reward investors who correctly anticipate inflection points. For Vext Science, watch Ohio cannabis regulatory developments and market oversupply risk as new operator licenses continue to be awarded in the state. EXoZymes' progress toward NCT market entry will be gated by FDA or equivalent regulatory pathway clarity—the most important binary event for the stock through 2026. Banzai's ConnectAndSell integration metrics in H2 2026 will determine whether the acquisition transforms revenue trajectory or stretches a balance sheet that already showed stress ahead of the deal.

Synthesized from 5 sources.